Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Wednesday 06 May, 2020

GlaxoSmithKline PLC

Result of AGM

RNS Number : 1848M
GlaxoSmithKline PLC
06 May 2020
 

GlaxoSmithKline plc

 

Results of Annual General Meeting

 

GlaxoSmithKline plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on Wednesday 6 May 2020.

 

As a result of the COVID-19 pandemic and the prohibition on public gatherings of more than two people, the AGM was held as a closed meeting attended by the minimum necessary quorum of two shareholders. All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

 

All resolutions were passed at the AGM and the results of the poll are set out below. The full text of the resolutions considered at the AGM are contained in the Notice of AGM published on 23 March 2020 which is available on GSK's website at www.gsk.com .

 

Commenting after the shareholder webcast, which was held after the AGM, Sir Jonathan Symonds, Chairman, said "Despite the current crisis which unfortunately meant that we could not hold our AGM in the usual way, I was pleased that we could engage with our shareholders via the webcast and that we were able to answer a number of questions. I would like to thank shareholders for their participation and for their continued support and understanding in these exceptional times".

 

Resolution

Total votes for (1)(2)

%

Total votes against (2)

%

Total votes cast

Votes withheld (3)

1

Receive and adopt the 2019 Annual Report

3,600,444,466

99.14

31,207,913

0.86

3,631,652,379

10,956,841

2

Approve the Annual report on remuneration  

3,420,333,315

94.53

197,813,171

5.47

3,618,146,486

24,463,063

3

To approve the Remuneration policy

2,665,161,732

88.18

357,360,021

11.82

3,022,521,753

620,087,463

4

Election of Sir Jonathan Symonds

3,608,718,661

99.35

23,502,289

0.65

3,632,220,950

10,386,063

5

Election of Charles Bancroft

3,627,334,204

99.87

4,856,095

0.13

3,632,190,299

10,417,951

6

Re-election of Emma Walmsley

3,627,591,812

99.84

5,958,848

0.16

3,633,550,660

9,058,990

7

Re-election of Vindi Banga

3,610,251,798

99.39

22,061,718

0.61

3,632,313,516

10,290,761

8

Re-election of Dr Hal Barron

3,626,272,920

99.83

6,065,354

0.17

3,632,338,274

10,268,248

9

Re-election of Dr Vivienne Cox

3,610,563,927

99.39

21,999,262

0.61

3,632,563,189

10,044,077

10

Re-election of Lynn Elsenhans

3,625,704,253

99.82

6,692,345

0.18

3,632,396,598

10,211,321

11

Re-election of Dr Laurie Glimcher

3,627,888,440

99.87

4,570,015

0.13

3,632,458,455

10,149,465

12

Re-election of Dr Jesse Goodman

3,627,512,409

99.87

4,791,872

0.13

3,632,304,281

10,303,639

13

Re-election of Judy Lewent

3,555,987,248

97.90

76,330,162

2.10

3,632,317,410

10,290,509

14

Re-election of Iain Mackay

3,589,348,335

98.83

42,624,938

1.17

3,631,973,273

10,634,976

15

Re-election of Urs Rohner

3,566,736,006

98.27

62,967,560

1.73

3,629,703,566

10,694,898

16

Re-appointment of the auditor

3,629,594,188

99.89

4,085,942

0.11

3,633,680,130

8,926,613

17

Remuneration of auditor

3,628,076,303

99.86

4,927,253

0.14

3,633,003,556

9,605,108

18

Authority for the company to make donations to political organisations and incur political expenditure

3,535,034,521

97.51

90,339,692

2.49

3,625,374,213

17,230,899

19

Authority to allot shares

3,486,912,340

96.08

142,428,115

3.92

3,629,340,455

13,259,348

20

Disapplication of pre-emption rights - general power (4)

3,551,097,589

97.88

76,802,232

2.12

3,627,899,821

14,698,767

21

Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment (4)

3,547,842,037

97.88

76,869,347

2.12

3,624,711,384

17,887,616

22

Authority for the company to purchase its own shares (4)

3,564,497,165

98.16

66,913,063

1.84

3,631,410,228

11,196,094

23

Exemption from statement of senior statutory auditor's name

3,584,838,016

98.78

44,131,049

1.22

3,628,969,065

13,635,791

24

Authority for reduced notice of a general meeting other than an AGM (4)

3,354,669,411

92.41

275,453,838

7.59

3,630,123,249

12,478,713

 

Notes:

 

(1)

The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.

(2)

Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3)

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(4)

Indicates Special Resolutions requiring a 75% majority.

 

The following table provides further relevant information:

 

 

 

GSK's

Twentieth

AGM

(2020)

 

GSK's

Nineteenth

AGM

(2019)

Issued share capital (excluding Treasury Shares)

5,017,091,542

4,987,806,108

Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)

72.60%

71.49%

Total shareholder population

105,353

108,698

Total number of proxies lodged

6,268

6,635

% of shareholders who lodged proxies

5.95%

6.10%

 

The above poll results will shortly be available on the Company's website at www.gsk.com . In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism  

 

 

 

 

V A Whyte

Company Secretary

 

6 May 2020

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGKKABNABKDAPK

a d v e r t i s e m e n t